HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of Convertible Debentures and Warrants

VANCOUVER, BC, July 21, 2022 /CNW/ - HAVN Life Sciences Inc. (CNSX:HAVN.CN) (OTC:HAVLF) (FSE:5NP) (the "Company" or "HAVN Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that Alpha Blue Ocean ("ABO") is supporting the Company's growth with a CAD$‎‎9,000,000 ‎‎financing arrangement whereby the Company will issue up to $10.6 million principal amount of Convertible Debentures (as defined below), which will include one initial tranche in the aggregate principal amount of $500,000 followed by up to ‎nineteen (19) subsequent tranches in the aggregate principal amount of $500,000 each over a period of 36-months (net cash to the Company for each tranche other than the first tranche to be $450,000 as described in greater detail below).